Skip to main content
ioGlutamatergic Neurons GBA null/N409S
bitbio-io1022-glutamatergic-neurons-GBA-null-n409s
bitbio-ioGlutamatergic-Neurons-media-kits
bit.bio-Reduced-glucocerebrosidase-activity-GBA-disease-model
bitbio-io1022-glutamatergic-neurons-gba-null-n409s-protein-expression-map2-tubb3-vglut2
bitbio-io1022-glutamatergic-neurons-gba-null-n409s-morphology
bit.bio-triculture-glutamatergic-neurons-astrocytes2-microglia-immunofluorescent-staining
mRNA transfection of human iPSC-derived neurons with GFP.
bitbio-mRNA-transfection-glutamatergic-neurons-GFP-quantification
bitbio-io1022-glutamatergic-neurons-GBA-null-n409s
bitbio-ioGlutamatergic-Neurons-media-kits
bit.bio-Reduced-glucocerebrosidase-activity-GBA-disease-model
bitbio-io1022-glutamatergic-neurons-gba-null-n409s-protein-expression-map2-tubb3-vglut2
bitbio-io1022-glutamatergic-neurons-gba-null-n409s-morphology
bit.bio-triculture-glutamatergic-neurons-astrocytes2-microglia-immunofluorescent-staining
mRNA transfection of human iPSC-derived neurons with GFP.
bitbio-mRNA-transfection-glutamatergic-neurons-GFP-quantification

cat no | io1022

ioGlutamatergic Neurons GBA null/N409S

Human iPSC-derived Gaucher and Parkinson’s disease model

  • Cryopreserved human iPSC-derived cells powered by opti-ox that are ready for experiments in days

  • Engineered to carry a GBA mutation relevant for modelling Gaucher and Parkinson's diseases

  • Consistent, functional excitatory neurons that form neuronal networks within days

Place your order

bitbio-io1022-glutamatergic-neurons-GBA-null-n409s

Human iPSC-derived Gaucher and Parkinson’s disease model

Representative ICC staining of ioGlutamatergic Neurons GBA null/N409S; MAP2 (red), VGLUT2 (green), DAPI (blue).

bitbio-ioGlutamatergic-Neurons-media-kits

ioGlutamatergic Neurons Media Kit

Cell culture media kit for the culture of ioGlutamatergic Neurons up to 14 days post-thaw

Learn more about the product >

bit.bio-Reduced-glucocerebrosidase-activity-GBA-disease-model

Reduced glucocerebrosidase activity demonstrated in disease model cells carrying GBA mutations

Glucocerebrosidase (GCase) activity was measured in ioGlutamatergic Neurons carrying mutations in the GBA gene (GBA null/R159W, GBA null/null and GBA null/N409S) or carrying SNCA A53T mutations (SNCA A53T/A53T and SNCA A53T/WT), and the wild-type genetically matched control.

Cells were seeded in 96-well plates (25,000 cells per well) and a fluorometric assay using 4-MUG as substrate was carried out on DIV9 to measure the enzymatic activity of GCase.

The assay confirmed that iPSC-derived glutamatergic neurons with GBA mutations showed significantly reduced GCase activity compared to the wild-type control and SNCA A53T disease models.

Statistical analysis: One-way ANOVA followed by Dunnett’s multiple comparison test versus isogenic control ***p<0.001.

Data courtesy of T. Loeffler et al., Scantox

View a complete dataset on a scientific poster

bitbio-io1022-glutamatergic-neurons-gba-null-n409s-protein-expression-map2-tubb3-vglut2

ioGlutamatergic Neurons GBA null/N409S express neuron-specific markers comparably to the wild-type control

Immunofluorescent staining on day 11 post-thaw demonstrates similar homogenous expression of pan-neuronal proteins TUBB3 and MAP2 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons GBA null/N409S compared to the genetically matched control (10X objective).

bitbio-io1022-glutamatergic-neurons-gba-null-n409s-morphology

ioGlutamatergic Neurons GBA null/N409S form structural neuronal networks by day 11

ioGlutamatergic Neurons GBA null/N409S mature rapidly and form structural neuronal networks over 11 days, when compared to the genetically matched control. Day 1 to 11 post thaw; 10X objective.

bit.bio-triculture-glutamatergic-neurons-astrocytes2-microglia-immunofluorescent-staining

Advanced tri-culture of ioGlutamatergic Neurons, ioAstrocytes 2.0, and ioMicroglia

While neuronal-astrocyte co-cultures capture essential structural and metabolic synergy, the addition of microglia, the resident myeloid cells of the CNS, is critical for accurately modelling neuroinflammatory pathways, synaptic pruning, and homeostatic maintenance.

This representative immunocytochemistry image demonstrates a successful tri-culture established at a 2:1:2 ratio (neurons:astrocytes:microglia). Using an optimised bit.bio protocol for 24-well plates, the tri-culture can be robustly maintained for up to 7 days. Staining with cell type-specific markers confirms the presence and integration of all three populations, shown alongside single-channel panels: MAP2-positive ioGlutamatergic Neurons (red), S100B-positive ioAstrocytes 2.0 (cyan), and IBA1-positive ioMicroglia (yellow); with DAPI as a nuclear counterstain (blue). Scale bars: 200 µm.

mRNA transfection of human iPSC-derived neurons with GFP.

Efficient mRNA transfection into ioGlutamatergic Neurons

ioGlutamatergic Neurons are efficiently transfected and show sustained long-term expression of mRNA encoding GFP. ioGlutamatergic Neurons were imaged from day 1 post-thaw and throughout the experiment to assess transfection efficiency and evaluate potential cytotoxic effects of the transfection protocol. Day 1 images were captured prior to transfection on the same day.

Download the step-by-step protocol for lipid-based delivery of synthetic mRNA into ioGlutamatergic Neurons.

bitbio-mRNA-transfection-glutamatergic-neurons-GFP-quantification

Lipid-based delivery of synthetic mRNA into ioGlutamatergic Neurons

ioGlutamatergic Neurons were transfected 24 hours post-thaw using Lipofectamine™ Stem Transfection Reagent. The transfection efficiency was evaluated by fluorescence imaging over 18 days after mRNA delivery, resulting in high transfection efficiency (close to 100%) and long-term sustained GFP expression.

Quantification of the GFP signal shows a decrease in GFP intensity over time, while the percentage of GFP-positive cells remains largely unchanged over time.

(A) The percentage of GFP-positive cells from two independent experiments.

(B) GFP intensity, quantified in successfully transfected cells from two independent experiments is quantified and normalised to day 2 (24 hours post-transfection).

Explore the full dataset and complete protocol for lipid-based delivery of synthetic mRNA in 96-well plates

Vial limit exceeded

A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.

Human iPSC-derived Gaucher and Parkinson’s disease model

ioGlutamatergic Neurons GBA null/N409S are opti‑ox deterministically programmed excitatory neurons carrying a genetically engineered compound heterozygous mutation in the GBA gene encoding the glucocerebrosidase (GCase) enzyme. These cells offer a rapidly maturing, human cell model to investigate modulation of GCase expression.

This variant, historically known as N370S, is now designated N409S under standardised nomenclature that accounts for the protein's 39-amino acid signal peptide.

Related Parkinson's disease model cells are available with GBA null/R159W, PINK1 Q456X, PRKN R275W and SNCA A53T mutations, and all can be used alongside their genetically matched control, ioGlutamatergic Neurons.

Benchtop benefits

comparison_0

Make true comparisons

Pair the ioDisease Model Cells with the genetically matched wild-type control to investigate the impact of the GBA mutation on molecular mechanisms and cell function.

scalable

Scalable

With opti-ox technology, we can make billions of consistently programmed cells, surpassing the demands of industrial workflows.

quick

Quick

The disease model cells and wil-type control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.

Cells arrive ready to plate


ioGlutamatergic_Neurons_and_disease_models_timeline

ioGlutamatergic Neurons GBA null/N409S are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.

Product specifications

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 48, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male (skin fibroblast),
Genotype APOE 3/4

Vial size

Small: >1 x 106 viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation

Differentiation method

opti-ox deterministic cell programming

Recommended seeding density

30,000 cells/cm2

User storage

LN2 or -150°C

Format

Cryopreserved cells

Genetic modification

Compound heterozygous null/N409S mutation in the GBA gene

Applications

Gaucher and Parkinson's disease research
Drug discovery and development
Disease modelling

Product use

ioCells are for research use only

 

Scale your study with volume pricing

Enabling scientists to use human cells in their research, running additional experiments without rationing cells or limiting experimental scale

 

Order quantity Total vials received Pricing tier 
1 - 9 packs 3 - 27 vials Standard price
10 - 33 packs 30 - 99 vials Automatic 10% discount
> 34 packs > 100 vials > Contact us for a quote

 

Academic pricing: Academic users can purchase any ioCells in 3-vial packs ($/€/£ 999 per pack), available year-round with any cell type combination.
Technical data

Highly characterised and defined

ioGlutamatergic Neurons GBA null/N409S express neuron-specific markers comparably to the wild-type control

bitbio-io1022-glutamatergic-neurons-gba-null-n409s-protein-expression-map2-tubb3-vglut2

Immunofluorescent staining on day 11 post-thaw demonstrates similar homogenous expression of pan-neuronal proteins TUBB3 and MAP2 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons GBA null/N409S compared to the genetically matched control (10X objective).

ioGlutamatergic Neurons GBA null/N409S form structural neuronal networks by day 11

bitbio-io1022-glutamatergic-neurons-gba-null-n409s-morphology

ioGlutamatergic Neurons GBA null/N409S mature rapidly and form structural neuronal networks over 11 days, when compared to the genetically matched control. Day 1 to 11 post thaw; 10X objective.

Industry leading seeding density

ioGlutamatergic_Neurons_seeding_density_small_96_384

The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar commercially available products. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.

How to culture ioGlutamatergic Neurons

In this video, our scientist will take you through the step-by-step process of how to thaw, seed and culture ioGlutamatergic Neurons.

How to prepare tissue culture vessels with PDL-Geltrex for culture

Dr Kaiser Karim will take you through the step-by-step process of coating your culture plate with PDL-Geltrex before the revival of ioGlutamatergic Neurons.

Since recording this video Geltrex has been replaced by Geltrex Flex; refer to the user manual for full details. 

Frequently Asked Questions (FAQs)

How was the GBA null/N409S genotype engineered?

The starting point for all ioGlutamatergic Neurons disease models is the parental opti-ox-enabled iPS cell line. CRISPR/Cas9 gene editing was used to introduce the null/N409S mutation. Genotyping confirmed that the null allele has a 55 base pair heterozygous deletion located in coding exon 9, causing a premature stop codon that disrupts the enzyme's active site across domains II and III. The second allele has a missense mutation, N409S (NM_000157.4(GBA1):c.1226A>G (p.Asn409Ser)).

 

Why is the N409S mutation in the GBA gene relevant for disease modelling?

Mutations in the GBA1 gene are the most common genetic risk factor for Parkinson’s disease (PD) and Lewy body dementia (LBD). In addition, Gaucher disease, an autosomal recessive disorder, is driven by bi-allelic GBA1 mutations. In patients, a pronounced deficit in glucocerebrosidase (GCase) activity drives severe lysosomal dysfunction and enhanced alpha-synuclein pathology. ioGlutamatergic Neurons carrying a compound heterozygous GBA null/N409S mutation pair a functionally absent allele with the most prevalent clinical missense mutation. By expressing this genotype in translationally relevant human excitatory neurons, this model offers an opportunity to screen GCase activators, gene therapies, and treatments targeting lysosomal storage and neurodegeneration.

 

Is there a genetically-matched wild-type control that can be used alongside the GBA disease model in human iPSC-derived glutamatergic neurons?

bit.bio offers the GBA null/N409S disease model and a genetically-matched wild-type control, which together provide a physiologically-relevant in vitro cell model to investigate the impact of the modulation of GCase expression.

 

Cell culture hacks | human iPSC-derived glutamatergic neurons

Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.

bit.bio_3x2_ioGlutamatergic Neurons_MAP2_Hoescht_x20_hi.res (1)

Wild Type and Isogenic Disease Model cells: A true comparison.

Further your disease research by pairing our wild type cells with isogenic disease models.

bitbio-vials-Wild_and_Disease-staggered-2500px_wide